OOIR: Observatory of International Research

Papers

(The H4-Index of Arthritis & Rheumatology is 49. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
	758
CCL19‐Positive Lymph Node Stromal Cells Govern the Onset of Inflammatory Arthritis via Tropomyosin Receptor Kinase	283
Classification Criteria for Axial Disease in Youth With Juvenile Spondyloarthritis	207
	153
Assessing the Immune Cell Subset and Genetic Mutations in Patients With Palindromic Rheumatism Seronegative for Rheumatoid Factor and Anti–Cyclic Citrullinated Peptide	151
No differences in myocardial perfusion between treatment‐naive, early rheumatoid arthritis patients and healthy controls	147
Seronegative palindromic rheumatism: what are we talking about? Comment on the article by Yang et al	144
The Evolving Role of the Rheumatology Practitioner in the Care of Immunocompromised Patients in the COVID‐19 Era	131
At the Heart of Treating Kawasaki Disease: The Search for New Approaches to Prevent Coronary Artery Aneurysms	127
The Devil Is in the Detail: Clinical Practice Guideline for the Optimal Timing of Elective Hip or Knee Arthroplasty	120
Association of change in metabolic syndrome status with altered risk of incident gout: comment on the article by Eun et al	120
Targeting the Myddosome in Systemic Autoimmunity: Ready for Prime Time?	115
Pregnancy Outcomes in Women With Psoriatic Arthritis in Relation to Presence and Timing of Antirheumatic Treatment	108
Possible confounding factors explaining data on heart failure risk in patients with polymyositis/dermatomyositis: comment on the article by Lin et al	104
Clinical Images: Rice bodies in pseudogout	104
Using Mice to Model Human Osteoarthritis: Age, Biologic Sex, and Pain Matter	101
Higher alcohol consumption was associated with greater incidence of total hip replacement due to hip osteoarthritis in a dose‐dependent manner in women: comment on the article by Marchand et al	99
Reply	96
Disturbed Spatial WNT Activation—A Potential Driver of the Reticularized Skin Phenotype in Systemic Sclerosis	91
Interleukin‐13 Receptor α1–Mediated Signaling Regulates Age‐Associated/Autoimmune B Cell Expansion and Lupus Pathogenesis	87
Gut Microbiome and Osteoarthritis: Insights From the Naturally Occurring Canine Model of Osteoarthritis	86
Role of Glutaminase 2 in Promoting CD4+ T Cell Production of Interleukin‐2 by Supporting Antioxidant Defense in Systemic Lupus Erythematosus	85
A methodologic problem and a conceptual issue related to the new 2022 antineutrophil cytoplasmic antibody–related vasculitis criteria sets: comment on criteria sets approved by the American College of	82
Endogenous Retroelement Activation is Implicated in Interferon‐α Production and Anti–Cyclic Citrullinated Peptide Autoantibody Generation in Early Rheumatoid Arthritis	80
Knee Alignment Correction by High Tibial Osteotomy Reduces Symptoms and Synovial Inflammation in Knee Osteoarthritis Accompanied by Macrophage Phenotypic Change From M1 to M2	79

Minimal tofacitinib dose for maintenance in axial spondyloarthritis: real‐world data from a resource‐limited setting	78
In This Issue	74
Clinical Connections	72
In This Issue	68
Systemic lupus erythematosus and atherosclerosis progression risk: comment on the article by Papazoglou et al.	64
Clinical Connections	62
Correction to “Novel Genetic Loci in Early‐Onset Gout Derived From Whole‐Genome Sequencing of an Adolescent Gout Cohort”	60
Identification of Shared and Asian‐Specific Loci for Systemic Lupus Erythematosus and Evidence for Roles of Type III Interferon Signaling and Lysosomal Function in the Disease: A	59
Phase III/IV, Randomized, Fifty‐Two–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus	58
Derivation of a Multivariable Psoriatic Arthritis Risk Estimation Tool (PRESTO): A Step Towards Prevention	57
Efficacy, Safety, Pharmacokinetics, and Immunogenicity of ABBV‐154 in Adults With Glucocorticoid‐Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Tr	55
Sex Differences in B Cells From the Joints of Children With Oligoarticular Juvenile Idiopathic Arthritis	55
Reply	55
COVID‐19 vaccine uptake and vaccine hesitancy in rheumatic disease patients receiving immunomodulatory therapies in community practice settings	54
Contribution of Interleukin‐4–Induced Epithelial Cell Senescence to Glandular Fibrosis in IgG4‐Related Sialadenitis	53
Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy	53
Efficacy and Safety of ABBV‐3373, a Novel Anti–Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody–Drug Conjugate, in Adults with Moderate‐to‐Severe Rheumatoid Arthr	53
Long‐Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis	53
The Interleukin‐1 Receptor–Associated Kinase 4 Inhibitor PF‐06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial	52
Incidence, Prevalence, and Mortality of Lupus Nephritis: A Population‐Based Study Over Four Decades Using the Lupus Midwest Network	52
Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled Trial	52
A Randomized, Double‐Blind, Placebo‐Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis	52
Alteration of Gut Microbiota in Individuals at High‐Risk for Rheumatoid Arthritis Associated With Disturbed Metabolome and the Initiation of Arthritis Through the Triggering of Mucosal Immu	51
2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases	50
	49
NLRP3 Attenuates Intraocular Inflammation by Inhibiting AIM2‐Mediated Pyroptosis Through the Phosphorylated Salt‐Inducible Kinase 1/Sterol Regulatory Element Binding T	49
The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria	49
	49